I Took Terbinafine Hcl 250 Mg and Did Not Finish the Dosage Can I Take It Again

What is Lamisil and how is it used?

Lamisil is a prescription medicine used to care for symptoms of fungus (Onychomycosis) of the toenail or fingernail. Lamisil may be used alone or with other medications.

Lamisil belongs to a class of drugs called Antifungals, Systemic.

It is not known if Lamisil is safe and effective in children.

What are the possible side effects of Lamisil?

Lamisil may cause serious side furnishings including:

• changes in your sense of taste or odor,
• depressed mood,
• slumber problems,
• lack of interest in daily activity,
• feeling anxious or restless,
• pale skin,
• piece of cake bruising,
• unusual bleeding (nose, mouth, vagina or rectum),
• majestic or red pinpoint spots under your skin
• ,
• swelling,
• rapid weight gain,
• little or no urinating,
• blood in your urine or stools,
• weight loss due to taste changes or loss of appetite,
• nausea,
• upper tummy pain,
• vomiting,
• tiredness,
• dark urine,
• clay-colored stools,
• yellowing of the skin or eyes (jaundice),
• skin sores, and
• butterfly-shaped skin rash on your cheeks or olfactory organ that worsens in sunlight

Go medical help right abroad, if you have whatever of the symptoms listed higher up.

The most common side effects of Lamisil include:

• diarrhea,
• nausea,
• gas,
• tummy pain or upset,
• rash,
• headache, and
• abnormal liver role tests

Tell your doctor if you lot have any side effect that bothers yous or that does not get away.

These are not all the possible side furnishings of Lamisil. For more data, ask your doctor or pharmacist.

Call your doctor for medical advice virtually side effects. Y'all may report side effects to FDA at ane-800-FDA-1088.

Description

Lamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride. Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-iv-ynyl)-N-methyl-1- naphthalenemethanamine hydrochloride. The empirical formula C₂₁H₂₆CIN with a molecular weight of 327.90, and the following structural formula:

Terbinafine hydrochloride is a white to off-white fine crystalline powder. It is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water.

Each tablet contains:

Agile Ingredients: terbinafine hydrochloride (equivalent to 250 mg base)

Inactive Ingredients: colloidal silicon dioxide NF, hydroxypropyl methylcellulose USP, magnesium stearate NF, microcrystalline cellulose NF, and sodium starch glycolate NF.

DOSAGE AND Assistants

Fingernail onychomycosis: One 250 mg tablet once daily for vi weeks.

Toenail onychomycosis: One 250 mg tablet once daily for 12 weeks.

The optimal clinical issue is seen some months afterwards mycological cure and cessation of treatment. Thisis related to the period required for outgrowth of salubrious nail.

HOW SUPPLIED

Dosage Forms And Strengths

Tablet, 250 mg white to yellow-tinged white circular, bi-convex, beveled tablets imprinted with "LAMISIL" in circular form on one side and code "250" on the other side.

Storage And Handling

Lamisil Tablets are supplied as white to yellow-tinged white circular, bi-convex, askew tablets containing 250 mg of terbinafine imprinted with "LAMISIL" in circular form on one side and lawmaking "250" on the other.

Bottles of 100 tablets NDC 0078-0179-05
Bottles of xxx tablets NDC 0078-0179-15

Shop Lamisil Tablets below 25°C (77°F); in a tight container. Protect from light.

Distributed by: Novartis Pharmaceuticals Corporation, Eastward Hanover, New Jersey 07936. Revised: Feb 2015

SIDE Furnishings

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of some other drug and may non reverberate the rates observed in practice.

The most often reported adverse events observed in the 3 U.s./Canadian placebo-controlled trials are listed in the table below. The adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia, and abdominal hurting), liver test abnormalities, rashes, urticaria, pruritus, and gustatory modality disturbances. Changes in the ocular lens and retina have been reported following the use of Lamisil Tablets in controlled trials. The clinical significance of these changes is unknown. In full general, the adverse events were balmy, transient, and did non lead to discontinuation from study participation.

	Adverse Event		Discontinuation
	Lamisil Tablets (%) n=465	Placebo (%) n=137	Lamisil Tablets (%) n=465	Placebo (%) n=137
Headache	12.9	9.5	0.2	0.0
Gastrointestinal Symptoms:
Diarrhea	five.six	2.nine	0.6	0.0
Dyspepsia	4.three	two.ix	0.4	0.0
Intestinal Pain	2.4	ane.5	0.4	0.0
Nausea	two.six	two.ix	0.2	0.0
Flatulence	two.2	2.2	0.0	0.0
Dermatological Symptoms:
Rash	five.6	2.2	0.ix	0.7
Pruritus	2.viii	one.5	0.two	0.0
Urticaria	one.1	0.0	0.0	0.0
Liver Enzyme Abnormalities*	3.3	one.4	0.2	0.0
Taste Disturbance	2.eight	0.seven	0.two	0.0
Visual Disturbance	1.1	ane.5	0.9	0.0
*Liver enzyme abnormalities ≥ 2x the upper limit of normal range.

Postmarketing Experience

The post-obit agin events have been identified during postapproval use of Lamisil Tablets. Considering these events are reported voluntarily from a population of uncertain size, information technology is not e'er possible to reliably judge their frequency or constitute a causal relationship to drug exposure.

Blood and lymphatic system disorders: Pancytopenia, agranulocytosis, severe neutropenia, thrombocytopenia, anemia [see WARNINGS AND PRECAUTIONS]

Allowed system disorders: Serious hypersensitivity reactions eastward.thou., angioedema and allergic reactions (including anaphylaxis), precipitation and exacerbation of cutaneous and systemic lupus erythematosus [see WARNINGS AND PRECAUTIONS], serum sickness-like reaction

Psychiatric disorders: Feet and depressive symptoms independent of sense of taste disturbance have been reported with utilize of Lamisil Tablets. In some cases, depressive symptoms have been reported to subside with discontinuance of therapy and to recur with reinstitution of therapy [see WARNINGS AND PRECAUTIONS].

Nervous arrangement disorders: Cases of taste disturbance, including gustatory modality loss, have been reported with the use of Lamisil Tablets. It can be severe enough to event in decreased food intake, weight loss, feet, and depressive symptoms. Cases of smell disturbance, including smell loss, have been reported with the utilise of Lamisil Tablets [come across WARNINGS AND PRECAUTIONS]. Cases of paresthesia and hypoesthesia take been reported with the use of Lamisil Tablets.

Heart disorders: Visual field defects, reduced visual acuity

Ear and labyrinth disorders: Hearing impairment, vertigo, tinnitus

Vascular disorders: Vasculitis

Gastrointestinal disorders: Pancreatitis, vomiting

Hepatobiliary disorders: Cases of liver failure some leading to liver transplant or decease [see WARNINGS AND PRECAUTIONS], idiosyncratic and symptomatic hepatic injury. Cases of hepatitis, cholestasis, and increased hepatic enzymes [see WARNINGS AND PRECAUTIONS] have been seen with the utilise of Lamisil Tablets.

Skin and subcutaneous tissue disorders: Serious pare reactions [east.one thousand., Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome] [see WARNINGS AND PRECAUTIONS], acute generalized exanthematous pustulosis, psoriasiform eruptions or exacerbation of psoriasis, photosensitivity reactions, hair loss

Musculoskeletal and connective tissue disorders: Rhabdomyolysis, arthralgia, myalgia

General disorders and administration site conditions: Malaise, fatigue, flu-like illness, pyrexia

Investigations: Altered prothrombin time (prolongation and reduction) in patients concomitantly treated with warfarin and increased blood creatine phosphokinase have been reported

DRUG INTERACTIONS

Drug-Drug Interactions

In vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized past the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of Lamisil Tablets should be done with careful monitoring and may require a reduction in dose of the 2D6- metabolized drug. In a study to appraise the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the assistants of terbinafine resulted in a 2-fold increase in Cmax and a 5-fold increment in area under the curve (AUC). In this study, these effects were shown to persist at the last observation at 4 weeks afterward discontinuation of Lamisil Tablets. In studies in salubrious subjects characterized as all-encompassing metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan/dextrorphan metabolite ratio in urine by 16- to 97-fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolizers to poor metabolizer status.

In vitro studies with man liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine, cisapride and fluvastatin. In vivo drug-drug interaction studies conducted in healthy volunteer subjects showed that terbinafine does non touch on the clearance of antipyrine or digoxin. Terbinafine decreases the clearance of caffeine by 19%. Terbinafine increases the clearance of cyclosporine by fifteen%.

The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant.

Coadministration of a single dose of fluconazole (100 mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine Cmax and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, information technology is likely that other inhibitors of both CYP2C9 and CYP3A4 (due east.g., ketoconazole, amiodarone) may likewise lead to a substantial increase in the systemic exposure (Cmax and AUC) of terbinafine when concomitantly administered.

In that location have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between Lamisil Tablets and these changes has non been established.

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. Terbinafine clearance is unaffected by cyclosporine. At that place is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers.

Nutrient Interactions

An evaluation of the effect of food on Lamisil Tablets was conducted. An increase of less than 20% of the AUC of terbinafine was observed when Lamisil Tablets were administered with food. Lamisil Tablets can be taken with or without food.

WARNINGS

Included as part of the PRECAUTIONS department.

PRECAUTIONS

Hepatotoxicity

Cases of liver failure, some leading to liver transplant or expiry, take occurred with the employ of Lamisil Tablets in individuals with and without preexisting liver disease.

In the majority of liver cases reported in clan with use of Lamisil Tablets, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may exist worse in patients with active or chronic liver disease. Treatment with Lamisil Tablets should exist discontinued if biochemical or clinical prove of liver injury develops.

Lamisil Tablets are not recommended for patients with chronic or active liver disease. Before prescribing Lamisil Tablets, liver office tests should be performed since hepatotoxicity may occur in patients with and without pre-existing liver illness. Periodic monitoring of liver role tests is recommended. Lamisil should exist immediately discontinued in case of elevation of liver function tests. Patients prescribed Lamisil Tablets should be warned to study immediately to their physician any symptoms of persistent nausea, anorexia, fatigue, airsickness, right upper intestinal pain or jaundice, dark urine, or pale stools. Patients with these symptoms should discontinue taking oral terbinafine, and the patient’s liver function should exist immediately evaluated.

Taste Disturbance Including Loss of Taste

Taste disturbance, including gustation loss, has been reported with the use of Lamisil Tablets. It tin be astringent enough to effect in decreased nutrient intake, weight loss, anxiety, and depressive symptoms. Taste disturbance may resolve inside several weeks after discontinuation of handling, but may be prolonged (greater than 1 year), or may be permanent. If symptoms of a taste disturbance occur, Lamisil Tablets should be discontinued.

Smell Disturbance Including Loss Of Smell

Smell disturbance, including loss of smell, has been reported with the use of Lamisil Tablets. Smell disturbance may resolve afterward discontinuation of treatment, but may exist prolonged (greater than 1 year), or may be permanent. If symptoms of a odor disturbance occur, Lamisil Tablets should be discontinued.

Depressive Symptoms

Depressive symptoms have occurred during postmarketing utilize of Lamisil Tablets. Prescribers should exist warning to the evolution of depressive symptoms, and patients should be instructed to written report depressive symptoms to their md.

Hematologic Effects

Transient decreases in accented lymphocyte counts (ALCs) accept been observed in controlled clinical trials. In placebo-controlled trials, 8/465 subjects receiving Lamisil Tablets (1.7%) and 3/137 subjects receiving placebo (two.ii%) had decreases in ALC to below 1000/mm³ on ii or more occasions. In patients with known or suspected immunodeficiency, physicians should consider monitoring consummate blood counts if treatment continues for more than 6 weeks. Cases of astringent neutropenia take been reported. These were reversible upon discontinuation of Lamisil Tablets, with or without supportive therapy. If clinical signs and symptoms suggestive of secondary infection occur, a consummate blood count should be obtained. If the neutrophil count is ≤ 1000 cells/mm³, Lamisil Tablets should be discontinued and supportive direction started.

Serious Skin/Hypersensitivity Reactions

There have been postmarketing reports of serious pare/hypersensitivity reactions [e.g., Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome]. Manifestations of DRESS syndrome may include cutaneous reaction (such every bit rash or exfoliative dermatitis), eosinophilia, and one or more organ complications such as hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. If progressive skin rash or signs/symptoms of the above drug reactions occur, handling with Lamisil Tablets should be discontinued.

Lupus Erythematosus

During postmarketing experience, precipitation and exacerbation of cutaneous and systemic lupus erythematosus accept been reported in patients taking Lamisil Tablets. Lamisil Tablets should be discontinued in patients with clinical signs and symptoms suggestive of lupus erythematosus.

Laboratory Monitoring

Measurement of serum transaminases (ALT and AST) is advised for all patients before taking Lamisil Tablets.

Patient Counseling Information

See FDA-Approved Patient Labeling (PATIENT Information)

Patients taking Lamisil Tablets should receive the following information and instructions:

• Advise patients to immediately study to their physician or get emergency help if they experience whatsoever of the following symptoms: hives, rima oris sores, baking and peeling of peel, swelling of face, lips, tongue, or throat, difficulty swallowing or breathing. Lamisil Tablets treatment should be discontinued.
• Advise patients to immediately report to their physician whatever symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper intestinal pain, jaundice, dark urine, or pale stools. Lamisil Tablets treatment should exist discontinued.
• Propose patients to report to their physician any signs of taste disturbance, odour disturbance and/or depressive symptoms, fever, skin eruption, lymph node enlargement, erythema, scaling, loss of pigment, and unusual photosensitivity that can result in a rash. Lamisil Tablets treatment should be discontinued.
• Suggest patients to minimize exposure to natural and artificial sunlight (tanning beds or UVA/B treatment) while using Lamisil Tablets.
• Advise patients that if they forget to have Lamisil Tablets, to take their tablets as shortly as they call up, unless it is less than four hours before the next dose is due. Advise patients to call their physician if they take too many Lamisil Tablets.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

In a 28-month oral carcinogenicity study in rats, an increment in the incidence of liver tumors was observed in males at the highest dose tested, 69 mg/kg/twenty-four hour period (2x the MRHD based on AUC comparisons of the parent terbinafine); nonetheless, fifty-fifty though dose-limiting toxicity was not achieved at the highest tested dose, college doses were non tested.

The results of a variety of in vitro (mutations in E. coli and S. typhimurium, DNA repair in rat hepatocytes, mutagenicity in Chinese hamster fibroblasts, chromosome abnormality, and sister chromatid exchanges in Chinese hamster lung cells), and in vivo (chromosome aberration in Chinese hamsters, micronucleus exam in mice) genotoxicity tests gave no testify of a mutagenic or clastogenic potential.

Oral reproduction studies in rats at doses up to 300 mg/kg/twenty-four hour period (approximately 12x the MRHD based on BSA comparisons) did not reveal whatever specific furnishings on fertility or other reproductive parameters. Intravaginal application of terbinafine hydrochloride at 150 mg/day in pregnant rabbits did not increase the incidence of abortions or premature deliveries nor affect fetal parameters.

Use In Specific Populations

Pregnancy

Pregnancy Category B

There are no acceptable and well-controlled studies in meaning women. Considering animal reproduction studies are non always predictive of human response, and considering treatment of onychomycosis can be postponed until after pregnancy is completed, information technology is recommended that Lamisil Tablets non be initiated during pregnancy.

Oral reproduction studies accept been performed in rabbits and rats at doses upward to 300 mg/kg/day [12x to 23x the maximum recommended human dose (MRHD), in rabbits and rats, respectively, based on trunk surface area (BSA) comparisons] and have revealed no evidence of impaired fertility or harm to the fetus due to terbinafine.

Nursing Mothers

Later on oral administration, terbinafine is nowadays in breast milk of nursing mothers. The ratio of terbinafine in milk to plasma is 7:i. Treatment with Lamisil Tablets is not recommended in women who are nursing.

Pediatric Use

The prophylactic and efficacy of Lamisil Tablets take not been established in pediatric patients with onychomycosis.

Geriatric Use

Clinical studies of Lamisil Tablets did not include sufficient numbers of subjects aged 65 years and over to determine whether they reply differently from younger subjects. Other reported clinical feel has non identified differences in responses betwixt the elderly and younger patients. In general, dose pick for an elderly patient should be cautious, usually starting at the depression cease of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac office, and of concomitant disease or other drug therapy.

Renal Impairment

In patients with renal harm (creatinine clearance less than or equal to l mL/min) the utilize of Lamisil Tablets has not been adequately studied.

Overdosage & Contraindications

OVERDOSE

Clinical experience regarding overdose with oral terbinafine is limited. Doses up to 5 grams (20 times the therapeutic daily dose) accept been taken without inducing serious adverse reactions. The symptoms of overdose included nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, and headache.

CONTRAINDICATIONS

Lamisil Tablets are contraindicated in individuals with a history of allergic reaction to oral terbinafine considering of the hazard of anaphylaxis.

CLINICAL PHARMACOLOGY

Machinery Of Activeness

Terbinafine is an allylamine antifungal [encounter Microbiology].

Pharmacodynamics

The pharmacodynamics of Lamisil Tablets is unknown.

Pharmacokinetics

Post-obit oral assistants, terbinafine is well captivated ( > seventy%) and the bioavailability of Lamisil Tablets as a result of first-pass metabolism is approximately 40%. Peak plasma concentrations of 1 μg/mL appear inside ii hours after a single 250 mg dose; the AUC is approximately 4.56 μg&bu;ll;h/mL. An increment in the AUC of terbinafine of less than 20% is observed when Lamisil Tablets are administered with nutrient.

In plasma, terbinafine is > 99% jump to plasma proteins and there are no specific bounden sites. At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours. Terbinafine is distributed to the sebum and skin. A terminal one-half-life of 200-400 hours may represent the dull elimination of terbinafine from tissues such as skin and adipose. Prior to excretion, terbinafine is extensively metabolized by at least 7 CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8, and CYP2C19. No metabolites have been identified that take antifungal action similar to terbinafine. Approximately 70% of the administered dose is eliminated in the urine.

In patients with renal impairment (creatinine clearance ≤ 50 mL/min) or hepatic cirrhosis, the clearance of terbinafine is decreased by approximately l% compared to normal volunteers. No outcome of gender on the blood levels of terbinafine was detected in clinical trials. No clinically relevant age-dependent changes in steady-country plasma concentrations of terbinafine have been reported.

Microbiology

Terbinafine, an allylamine antifungal, inhibits biosynthesis of ergosterol, an essential component of fungal prison cell membrane, via inhibition of squalene epoxidase enzyme. This results in fungal cell decease primarily due to the increased membrane permeability mediated by the accumulation of high concentrations of squalene but non due to ergosterol deficiency. Depending on the concentration of the drug and the fungal species test in vitro, terbinafine hydrochloride may exist fungicidal. However, the clinical significance of in vitro data is unknown.

Terbinafine has been shown to be agile confronting most strains of the post-obit microorganisms both in vitro and in clinical infections:

Trichophyton mentagrophytes
Trichophyton rubrum

The following in vitro data are bachelor, but their clinical significance is unknown. In vitro, terbinafine exhibits satisfactory MIC's against most strains of the following microorganisms; however, the safety and efficacy of terbinafine in treating clinical infections due to these microorganisms have non been established in adequate and well-controlled clinical trials:

Candida albicans
Epidermophyton floccosum
Scopulariopsis brevicaulis

Animal Toxicology And/Or Pharmacology

A wide range of in vivo studies in mice, rats, dogs, and monkeys, and in vitro studies using rat, monkey, and man hepatocytes suggest that peroxisome proliferation in the liver is a rat-specific finding. All the same, other furnishings, including increased liver weights and APTT, occurred in dogs and monkeys at doses giving Css trough levels of the parent terbinafine 2-3x those seen in humans at the MRHD. College doses were not tested.

Clinical Studies

The efficacy of Lamisil Tablets in the treatment of onychomycosis is illustrated by the response of subjects with toenail and/or fingernail infections who participated in iii The states/Canadian placebo-controlled clinical trials.

Results of the get-go toenail trial, as assessed at week 48 (12 weeks of handling with 36 weeks follow-up after completion of therapy), demonstrated mycological cure, defined as simultaneous occurrence of negative KOH plus negative civilisation, in 70% of subjects. Fifty-nine percent (59%) of subjects experienced effective handling (mycological cure plus 0% nail involvement or > 5mm of new unaffected nail growth); 38% of subjects demonstrated mycological cure plus clinical cure (0% nail interest).

In a second toenail trial of dermatophytic onychomycosis, in which nondermatophytes were too cultured, similar efficacy against the dermatophytes was demonstrated. The pathogenic role of the nondermatophytes cultured in the presence of dermatophytic onychomycosis has not been established. The clinical significance of this clan is unknown.

Results of the fingernail trial, as assessed at week 24 (half-dozen weeks of handling with 18 weeks follow-upwardly later completion of therapy), demonstrated mycological cure in 79% of subjects, effective treatment in 75% of the subjects, and mycological cure plus clinical cure in 59% of the subjects.

The mean time to overall success was approximately 10 months for the outset toenail trial and iv months for the fingernail trial. In the start toenail trial, for subjects evaluated at to the lowest degree 6 months afterward achieving clinical cure and at to the lowest degree 1 year subsequently completing therapy with Lamisil Tablets, the clinical relapse rate was approximately 15%.

PATIENT Data

Lamisil
(Lam-i-sil)
(terbinafine hydrochloride) Tablets

What are Lamisil Tablets ?

Lamisil Tablets is a prescription antifungal medicine used to care for fungal infections of the fingernails and toenails (onychomycosis).

Your physician should do tests to check you for fungal infection of your nails earlier y'all commencement Lamisil Tablets.

It is not known if Lamisil Tablets are safe and effective in children for the handling of onychomycosis.

Who should not accept Lamisil Tablets ?

Do not take Lamisil Tablets if yous are allergic to terbinafine hydrochloride when taken by oral fissure.

What should I tell my md before taking Lamisil Tablets ?

Before yous take Lamisil Tablets , tell your doctor if you:

• take or had liver issues
• have a weakened immune system (immunocompromised)
• have lupus (an autoimmune disease)
• have whatever other medical weather condition
• are pregnant or programme to get pregnant. Information technology is not known if Lamisil Tablets will harm your unborn baby. Y'all should not get-go taking Lamisil Tablets during pregnancy without talking with your medico.
• are breastfeeding or plan to breastfeed. Lamisil can pass into your breast milk and may damage your baby. Talk to your doc about the all-time way to feed your babe if yous take Lamisil Tablets.

Tell your md well-nigh all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Lamisil Tablets may affect the mode other medicines work and other medicines may bear upon how Lamisil Tablets work. Especially tell your medico if you accept:

• a medicine for low
• a medicine for loftier blood pressure
• a medicine for heart bug
• desipramine (Norpramin)
• caffeine
• cyclosporine (Gengraf, Neoral, Sandimmune)
• fluconazole (Diflucan)
• rifampin (Rifater, Rifamate, Rimactane, Rifadine)
• cimetidine (Tagamet)

If y'all are non sure if your medicine is i listed above, ask your doctor or pharmacist.

Know the medicines you take. Keep a list of them to show your physician and chemist when y'all get a new medicine.

How should I have Lamisil Tablets ?

• Take Lamisil Tablets exactly as your doctor tells you to take it.
• Lamisil comes equally a tablet that y'all take by oral cavity.
• Lamisil Tablets are normally taken:
  • 1 time each day for 6 weeks to care for fungal infections of your fingernail, or
  • 1 fourth dimension each day for 12 weeks to care for fungal infections of your toenail
• Lamisil Tablets can be taken with or without food.
• If yous miss a dose of Lamisil Tablets, take information technology as shortly as you think. If it is less than iv hours earlier your next dose, skip the missed dose. Just take the next dose at your regular time.

If you take likewise many Lamisil Tablets telephone call your dr.. You may take the post-obit symptoms:

• nausea
• vomiting
• tummy (belly) pain
• dizziness
• rash
• frequent urination
• headache

What should I avert while taking Lamisil Tablets ?

• Avoid sunlight. Lamisil Tablets can brand your skin sensitive to the sun and the light from sunlamps and tanning beds. You tin become a astringent sunburn. Employ sunscreen and wear a hat and dress that cover your skin if you accept to be in sunlight. Talk to your doctor if you lot get sunburn.

What are the possible side furnishings of Lamisil Tablets ?

Lamisil Tablets may cause serious side effects, including:

• liver problems that tin can pb to the need for liver trans plant, or death. Tell your physician correct away if y'all become whatsoever of these symptoms of a liver problem:
  • nausea
  • upper right breadbasket-area (abdomen) pain
  • poor appetite
  • yellowing of your skin or optics (jaundice)
  • tiredness
  • night (tea-colored) urine
  • airsickness
  • pale or calorie-free colored stools

Your doc should do a claret exam to check you for liver issues earlier yous accept Lamisil Tablets.

• change in gustatory modality or los s of gustation may happen with Lamisil Tablets and can be severe. This may better within several weeks subsequently you stop taking Lamisil Tablets, merely may terminal for a long fourth dimension or may go permanent. Tell your doctor if yous have:
  • change in sense of taste or loss of taste
  • poor ambition
  • unwanted weight loss
  • anxiousness
  • change in mood or depressive symptoms
• change in smell or loss of odor may happen with Lamisil Tablets. This may amend after you stop taking Lamisil Tablets, but may last for a long time or may get permanent.
• depressive symptoms. Tell your md right away if you have any of these signs or symptoms:
  • experience sad or worthless
  • modify in sleep blueprint
  • loss of free energy or interest in daily activities
  • restlessness
  • mood changes
• low white claret cell count. People taking Lamisil Tablets may have a subtract in white blood cells, particularly neutrophils. Yous may have a higher risk of getting an infection when your white blood cell count is low.
• serious pare or allergic reactions. Tell your doctor correct away or get emergency assist if you get whatsoever of these symptoms:
  • pare rash, hives, sores in your mouth, or your skin blisters and peels
  • swelling of your face, optics, lips, tongue or throat, problem swallowing or breathing
  • drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome – peel rash, fever, swollen lymph glands, involvement of internal organs
• new or worsening lupus (an autoimmune disease). Stop taking Lamisil Tablets and tell your doctor if y'all become any of the following:
  • progressive skin rash that is scaly, red, shows scarring, or loss of pigment
  • unusual sensitivity to the sunday that can lead to a rash

The most common side effects of Lamisil Tablets include:

• headache
• diarrhea
• rash
• upset tum
• abnormal liver function tests
• itching
• change in taste
• nausea
• stomach-area (abdomen) pain
• gas

Tell your doctor if you lot have any side effect that bothers you or that does not go abroad.

These are not all of the possible side effects of Lamisil Tablets. For information, ask your doctor or chemist.

Phone call your doctor for medical communication near side furnishings. You may study side furnishings to FDA at one-800-FDA-1088.

How should I store Lamisil Tablets ?

• Shop Lamisil Tablets beneath 77°F (25°C)
• Keep Lamisil Tablets in a tightly closed container and keep out of the light.

Continue Lamisil Tablets and all medicines out of the reach of children.

Full general information about the safe and effective utilise of Lamisil Tablets .

Medicines are sometimes prescribed for purposes other than those listed in Patient Information. Exercise non apply Lamisil Tablets for a condition for which information technology was not prescribed. Do non give Lamisil Tablets to other people, fifty-fifty if they accept the aforementioned symptoms that you take. Information technology may harm them.

Y'all tin ask your pharmacist or dr. for information near Lamisil Tablets that is written for health professionals.

What are the ingredients in Lamisil Tablets ?

Active ingredient: terbinafine hydrochloride

Inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate

This Patient Data has been approved by the U.S. Food and Drug Administration.

From

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

hernandeztesto1985.blogspot.com

Source: https://www.rxlist.com/lamisil-drug.htm

Share this post